BridgeBio saw significant revenue growth in Q4 2025, primarily driven by the commercial success of Attruby (acoramidis) following its 2024 FDA approval. The company achieved three positive Phase 3 trial readouts in late 2025 and is preparing for multiple NDA submissions in 1H 2026, transitioning into a multi-product commercial-stage biopharmaceutical company.
Total Q4 revenue reached $154.2 million, a massive increase from $5.9 million in the prior year, driven by Attruby net product sales.
Reported three positive Phase 3 trial readouts (PROPEL 3, FORTIFY, and CALIBRATE) within a three-month window.
On track for two NDA submissions in 1H 2026 for BBP-418 (LGMD2I/R9) and encaleret (ADH1).
Strengthened balance sheet with $587.5 million in cash and a subsequent $632.5 million convertible note issuance in January 2026.
BridgeBio is focused on expanding its commercial portfolio from one to potentially six approved medicines by the end of its first decade, supported by recent Phase 3 successes.
Analyze how earnings announcements historically affect stock price performance